200 Inner Belt Road
Suite 400
Somerville, MA 02143
United States
617 229 6499
https://www.finchtherapeutics.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 189
Nombre | Título | Paga | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Dr. Mark Burnham Smith Ph.D. | CEO & Director | 698,66k | N/A | 1987 |
Mr. Marc B. Blaustein C.F.A., CFA, MPP | COO, Principal Financial & Accounting Officer | 378,21k | N/A | 1963 |
Mr. Joseph D. Vittiglio Esq., J.D. | Chief Bus. & Legal Officer and Corp. Sec. | 526,08k | N/A | 1972 |
Mr. Bryan Gillis M.B.A. | Chief Technology Officer | N/A | N/A | N/A |
Mr. James S. Sigler | Exec. VP of CMC | N/A | N/A | 1961 |
Ms. Sonia Timberlake | Sr. VP of Research | N/A | N/A | N/A |
Dr. Howard Franklin M.B.A., M.D. | Interim Chief Medical Officer | N/A | N/A | N/A |
Dr. Alka Batycky Ph.D. | Chief Devel. Officer | N/A | N/A | N/A |
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.
El ISS Governance QualityScore de Finch Therapeutics Group, Inc., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.